BUZZ-Structure Therapeutics doubles while other obesity drug developers decline

Reuters2025-12-31
BUZZ-Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> doubles while other obesity drug developers decline

** Shares of Structure Therapeutics GPCR.O have more than doubled this year, after declining 33% in 2024

** Structure earlier this month said its experimental oral obesity pill showed 11.3% reduction in weight at 120 mg dose at 36 weeks in mid-stage study

** Shares of other obesity drug developers such as Viking Therapeutics VKTX.O and Altimmune ALT.O are set to end in red

** Weight-loss drug market is surging, with biotech firms racing to win share in sector dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N

** Analysts forecast the industry will generate about $150 billion in annual sales in the next decade

** Shares of Viking are down 12.2% this year after more than doubling in 2024; company said its experimental weight-loss pill helped patients lose 12.2% of their body weight in mid-stage trial, missing Wall Street's top-end expectations of 15%

** Shares of Altimmune have fallen 49.9% this year, set for third straight year of declines

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment